Argos Therapeutics Inc. (NASDAQ:ARGS)’s share price traded down 10.7% on Tuesday . The company traded as low as $4.62 and last traded at $4.66, with a volume of 337,870 shares traded. The stock had previously closed at $5.22.

A number of equities analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Friday, June 17th. FBR & Co restated a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, May 14th. Zacks Investment Research upgraded shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research report on Tuesday, May 17th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $11.00 target price on shares of Argos Therapeutics in a report on Monday, June 20th. Eight research analysts have rated the stock with a buy rating, Argos Therapeutics has an average rating of “Buy” and an average price target of $11.50.

The stock’s 50 day moving average price is $5.30 and its 200-day moving average price is $5.92. The company’s market cap is $196.92 million.

Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. On average, analysts anticipate that Argos Therapeutics Inc. will post ($1.49) earnings per share for the current fiscal year.

In related news, major shareholder International S. Pharmstandard purchased 75,474 shares of the business’s stock in a transaction dated Monday, August 22nd. The stock was acquired at an average price of $4.24 per share, for a total transaction of $320,009.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder International S. Pharmstandard purchased 67,371 shares of the business’s stock in a transaction dated Wednesday, August 24th. The stock was bought at an average price of $4.52 per share, with a total value of $304,516.92. The disclosure for this purchase can be found here.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.